OTCPK:ANPC.F

Stock Analysis Report

Executive Summary

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.

Risks

  • ANGLE is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has ANGLE's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

ANPC.F

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

n/a

ANPC.F

9.9%

US Medical Equipment

0.6%

US Market

No trading data on ANPC.F.

No trading data on ANPC.F.


Share holder returns

ANPC.FIndustryMarket
7 Day0%1.1%-0.6%
30 Day0%0.6%2.2%
90 Day0%2.9%1.1%
1 Yearn/a10.8%9.9%2.9%0.6%
3 Yearn/a70.1%64.9%44.6%35.2%
5 Yearn/a138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is ANGLE's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ANGLE undervalued based on future cash flows and its price relative to the stock market?

2.93x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for ANGLE to establish if it is available at moderate discount.

Unable to calculate intrinsic value for ANGLE to establish if it is available at substantial discount.


Price Based on Earnings

ANGLE is loss making, we can't compare its value to the US Medical Equipment industry average.

ANGLE is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for ANGLE, we can't assess if its growth is good value.


Price Based on Value of Assets

ANGLE is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is ANGLE expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

80.1%

Forecasted annual revenue growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

ANGLE's revenue is expected to grow significantly at over 20% yearly.

Unable to determine if ANGLE is high growth as no earnings estimate data is available.

ANGLE's revenue growth is expected to exceed the United States of America market average.

Unable to compare ANGLE's earnings growth to the United States of America market average as no estimate data is available.

Unable to compare ANGLE's earnings growth to the low risk savings rate as no estimate data is available.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if ANGLE will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has ANGLE performed over the past 5 years?

-30.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

ANGLE does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare ANGLE's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare ANGLE's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if ANGLE has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if ANGLE has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if ANGLE improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is ANGLE's financial position?


Financial Position Analysis

ANGLE is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

ANGLE has no long term commitments.


Debt to Equity History and Analysis

ANGLE has no debt.

ANGLE has no debt compared to 5 years ago when it was 2.1%.


Balance Sheet

Low level of unsold assets.

ANGLE has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

ANGLE has sufficient cash runway for 1.6 years based on current free cash flow.

ANGLE has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 25.4% each year.


Next Steps

Dividend

What is ANGLE's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate ANGLE's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate ANGLE's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as ANGLE has not reported any payouts.

Unable to verify if ANGLE's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as ANGLE has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of ANGLE's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average management tenure


CEO

Andrew David Newland (56yo)

0yrs

Tenure

UK£336,000

Compensation

Mr. Andrew David William Newland, Meng, ACA founded ANGLE Plc in 1994 and serves as its Group Chief Executive. Mr. Newland founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nu ...


CEO Compensation Analysis

Andrew David's remuneration is about average for companies of similar size in United States of America.

Andrew David's compensation has increased whilst company is loss making.


Management Age and Tenure

1.5yrs

Average Tenure

53yo

Average Age

The average tenure for the ANGLE management team is less than 2 years, this suggests a new team.


Board Age and Tenure

9.1yrs

Average Tenure

56yo

Average Age

The tenure for the ANGLE board of directors is about average.


Insider Trading

No 3 month insider trading information.


Ownership Breakdown


Management Team

  • Andrew David Newland (56yo)

    Founder

    • Tenure: 0yrs
    • Compensation: UK£336.00k
  • Ian Griffiths (53yo)

    CFO, Finance Director

    • Tenure: 15.3yrs
    • Compensation: UK£216.00k
  • Daniel O'Shannessy

    Chief Scientific Officer

    • Tenure: 1.4yrs
  • Paul Smith

    VP & Chief Executive Officer of ANGLE Biosciences Inc

    • Tenure: 1.6yrs
  • Martin Cooke (49yo)

    Director of Manufacturing & Regulatory Affairs

    • Tenure: 1.4yrs
  • Michael O'Brien

    Business Development Director

    • Tenure: 5.6yrs
  • Greg Shaw

    Scientific Advisor & Member of Scientific Advisory Board

    • Tenure: 0yrs

Board Members

  • Harold Swerdlow

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Garth Selvey (69yo)

    Non-Executive Chairman

    • Tenure: 11.8yrs
    • Compensation: UK£20.00k
  • Andrew David Newland (56yo)

    Founder

    • Tenure: 0yrs
    • Compensation: UK£336.00k
  • Ian Griffiths (53yo)

    CFO, Finance Director

    • Tenure: 15.3yrs
    • Compensation: UK£216.00k
  • Ashok Venkitaraman

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Brian Howlett (73yo)

    Non-Executive Director

    • Tenure: 6.4yrs
    • Compensation: UK£20.00k
  • Clive Stanway

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Adrian Newland

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • George Hvichia (56yo)

    Member of Scientific Advisory Board

    • Tenure: 1.4yrs
  • Jim Reuben

    Member of Scientific Advisory Board

    • Tenure: 4yrs
  • Greg Shaw

    Scientific Advisor & Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

ANGLE plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ANGLE plc
  • Ticker: ANPC.F
  • Exchange: OTCPK
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£79.716m
  • Listing Market Cap: UK£100.482m
  • Shares outstanding: 143.37m
  • Website: https://www.angleplc.com

Number of Employees


Location

  • ANGLE plc
  • The Surrey Research Park
  • 10 Nugent Road
  • Guildford
  • Surrey
  • GU2 7AF
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGLAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPMar 2004
ANPC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMar 2004
DWVDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2004
ANPC.YOTCPK (Pink Sheets LLC)SPONSONRED ADRUSUSDOct 2014

Biography

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests rare circulating tum ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/06/17 00:03
End of Day Share Price2019/03/19 00:00
Earnings2018/10/31
Annual Earnings2018/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.